| 27.4 1.28 (4.9%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.04  |
1-year : | 44.43 |
| Resists | First : | 32.56 |
Second : | 38.04 |
| Pivot price | 28.22 |
|||
| Supports | First : | 25.71 |
Second : | 21.47 |
| MAs | MA(5) : | 27.29  |
MA(20) : | 26.87 |
| MA(100) : | 25.49 |
MA(250) : | 23.98 |
|
| MACD | MACD : | 0.9 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 44.3 |
D(3) : | 48.8 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 33.63 | Low : | 16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PRPO ] has closed above bottom band by 40.2%. Bollinger Bands are 45.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.79 - 27.95 | 27.95 - 28.09 |
| Low: | 24.11 - 24.29 | 24.29 - 24.46 |
| Close: | 27.1 - 27.4 | 27.4 - 27.67 |
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Fri, 04 Sep 2026
Precipio Inc. (PRPO) Peer Comparison – Compare with Others - Value Research
Fri, 04 Sep 2026
Precipio Inc. (PRPO) Key Financial Ratios – Valuation, Profitability & More - Value Research
Thu, 03 Sep 2026
Precipio Inc. (PRPO) Slips 2.36% to $26.85 as Shares Approach Key Support Zone - Call Wall - dars.gov.et
Fri, 28 Aug 2026
Precipio Stock Price Forecast. Should You Buy PRPO? - StockInvest.us
Mon, 24 Aug 2026
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - TradingView
Sat, 22 Aug 2026
PRPO | Precipio, Inc. Common Stock Financials - Revenue Breakdown - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 17.7 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 27 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.18 |
| Profit Margin | -3.6 % |
| Operating Margin | -21.3 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -7.2 % |
| Qtrly Rev. Growth | 36.2 % |
| Gross Profit (p.s.) | 6.3 |
| Sales Per Share | 14.43 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -44.2 |
| PEG Ratio | 0 |
| Price to Book value | 3.34 |
| Price to Sales | 1.89 |
| Price to Cash Flow | 61.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|